Barclays analyst Balaji Prasad raised the firm’s price target on Dr. Reddy’s to $75 from $70 and keeps an Overweight rating on the shares. The company’s fiscal Q2 performance was strong and its biosimilars pipeline progressed with preapproval inspections for U.S. and European facilities, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDY: